103 related articles for article (PubMed ID: 3035023)
21. IFN-gamma- and cell-to-cell contact-dependent cytotoxicity of allograft-induced macrophages against syngeneic tumor cells and cell lines: an application of allografting to cancer treatment.
Yoshida R; Yoneda Y; Kuriyama M; Kubota T
J Immunol; 1999 Jul; 163(1):148-54. PubMed ID: 10384111
[TBL] [Abstract][Full Text] [Related]
22. In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice.
Shu S; Chou T; Rosenberg SA
Cancer Res; 1987 Mar; 47(5):1354-60. PubMed ID: 3102046
[TBL] [Abstract][Full Text] [Related]
23. src-specific immune regression of Rous sarcoma virus-induced tumors.
Gelman IH; Hanafusa H
Cancer Res; 1993 Feb; 53(4):915-20. PubMed ID: 8381333
[TBL] [Abstract][Full Text] [Related]
24. Enhancement of immunity against RSV-induced sarcomas by generation of hapten-reactive helper T lymphocytes.
Comoglio PM; Prat M; Bretti S
Immunology; 1985 Feb; 54(2):289-95. PubMed ID: 2578431
[TBL] [Abstract][Full Text] [Related]
25. Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen.
Tüting T; Gambotto A; Robbins PD; Storkus WJ; DeLeo AB
Gene Ther; 1999 Apr; 6(4):629-36. PubMed ID: 10476222
[TBL] [Abstract][Full Text] [Related]
26. Morphological transformation, tumorigenicity and src-specific cytotoxic T-lymphocyte-mediated tumor immunity induced by murine 3T3 cells expressing src oncogenes encoding novel non-myristylated N-terminal domains.
Gelman IH; Khan S; Hanafusa H
Oncogene; 1993 Nov; 8(11):2995-3004. PubMed ID: 7692370
[TBL] [Abstract][Full Text] [Related]
27. Role of L3T4+ and LyT-2+ cells in experimental visceral leishmaniasis.
Stern JJ; Oca MJ; Rubin BY; Anderson SL; Murray HW
J Immunol; 1988 Jun; 140(11):3971-7. PubMed ID: 3131421
[TBL] [Abstract][Full Text] [Related]
28. Enhancement of passive antilisterial immunity and change of Lyt phenotype following in vitro stimulation of murine lymphoid cells from immune donors.
Barry RA; Hinrichs DJ
Clin Invest Med; 1984; 7(4):303-9. PubMed ID: 6442653
[TBL] [Abstract][Full Text] [Related]
29. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.
Mulé JJ; Yang JC; Afreniere RL; Shu SY; Rosenberg SA
J Immunol; 1987 Jul; 139(1):285-94. PubMed ID: 3108401
[TBL] [Abstract][Full Text] [Related]
30. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity.
Bannerji R; Arroyo CD; Cordon-Cardo C; Gilboa E
J Immunol; 1994 Mar; 152(5):2324-32. PubMed ID: 7907636
[TBL] [Abstract][Full Text] [Related]
31. The augmentation of surface Ly-6A/E molecules in activated T cells is mediated by endogenous interferon-gamma.
Dumont FJ; Boltz RC
J Immunol; 1987 Dec; 139(12):4088-95. PubMed ID: 3121727
[TBL] [Abstract][Full Text] [Related]
32. Characterization of T lymphocytes mediating in vivo protection against RSV-induced murine sarcomas.
Prat M; Di Renzo MF; Comoglio PM
Int J Cancer; 1983 Jun; 31(6):757-64. PubMed ID: 6305851
[TBL] [Abstract][Full Text] [Related]
33. Demonstration of intratumoral infiltration of tumor-specific Lyt-1+2- T cells mediating delayed-type hypersensitivity response and in vivo protective immunity.
Tomita S; Fujiwara H; Yamane Y; Sano S; Nakajima H; Izumi Y; Arai H; Kawanishi Y; Tsuchida T; Hamaoka T
Jpn J Cancer Res; 1986 Feb; 77(2):182-9. PubMed ID: 3082830
[TBL] [Abstract][Full Text] [Related]
34. Immunization with wild-type p53 gene sequences coadministered with Flt3 ligand induces an antigen-specific type 1 T-cell response.
Parajuli P; Pisarev V; Sublet J; Steffel A; Varney M; Singh R; LaFace D; Talmadge JE
Cancer Res; 2001 Nov; 61(22):8227-34. PubMed ID: 11719454
[TBL] [Abstract][Full Text] [Related]
35. The role of IFN-gamma in rejection of established tumors by IL-12 : source of production and target.
Segal JG; Lee NC; Tsung YL; Norton JA; Tsung K
Cancer Res; 2002 Aug; 62(16):4696-703. PubMed ID: 12183428
[TBL] [Abstract][Full Text] [Related]
36. Radiosensitive barrier to T-cell-mediated adoptive immunotherapy of established tumors.
Awwad M; North RJ
Cancer Res; 1990 Apr; 50(8):2228-33. PubMed ID: 2317810
[TBL] [Abstract][Full Text] [Related]
37. Cytotoxic CD4+ T cells associated with the expression of major histocompatibility complex class II antigen of mouse myeloma cells secreting interferon-gamma are cytolytic in vitro and tumoricidal in vivo.
Xiang J; Moyana T
Cancer Gene Ther; 1998; 5(5):313-20. PubMed ID: 9824051
[TBL] [Abstract][Full Text] [Related]
38. Cytolytic activity of murine CD4+ T cell clones correlates with IFN-gamma production in mouse strains having a BALB/c background.
McKisic MD; Lancki DW; Fitch FW
J Immunol; 1993 May; 150(9):3793-805. PubMed ID: 8097225
[TBL] [Abstract][Full Text] [Related]
39. Adoptive cell transfer studies to examine the role of T lymphocytes in immunity to Trypanosoma musculi.
House RV; Dean JH
J Parasitol; 1988 Oct; 74(5):819-27. PubMed ID: 2971101
[TBL] [Abstract][Full Text] [Related]
40. Critical involvement of interferon gamma in the pathogenesis of T-cell activation-associated hepatitis and regulatory mechanisms of interleukin-6 for the manifestations of hepatitis.
Mizuhara H; Uno M; Seki N; Yamashita M; Yamaoka M; Ogawa T; Kaneda K; Fujii T; Senoh H; Fujiwara H
Hepatology; 1996 Jun; 23(6):1608-15. PubMed ID: 8675184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
